



Arrowhead Pharmaceuticals, Inc.
Investor Relations Department
225 South Lake Avenue
Suite 1050
Pasadena, CA 91101
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

NASDAQ: ARWR

Last Trade:	3.89
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.20 - 6.76
Volume	N/A


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 23, 2017*
[Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635\(c\)\(4\)](#)
- Oct 23, 2017*
[Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017](#)
- Oct 10, 2017*
[Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®](#)
- Oct 3, 2017*
[Arrowhead to Present at Chardan Gene Therapy Conference](#)
- Sep 27, 2017*
[Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Dec 14, 2016*
[Annual Report \(10-K\)](#)
- Feb 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*
[Quarterly Report \(10-Q\)](#)
- May 3, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017*
[Quarterly Report \(10-Q\)](#)